Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) reported upbeat results from Phase 1 and Phase 2 studies its cystic fibrosis treatment. The stock price leaped $27.53 to close at $159.69.
Upbeat study results for Vertex Pharmaceuticals
July 19, 2017 at 17:20 PM EDT
